Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q1 FY26 results · Apr–Jun 2025
Solara Active Pharma Sciences reported revenue from operations of ₹319.15 crore (down 12.2% from Q1 FY25) and net profit of ₹10.52 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 319.15 | 363.49 | −12.2% | 273.01 | +16.9% |
| Other income | 0.98 | 0.56 | +75.0% | 5.95 | −83.5% |
| Total income | 320.13 | 364.05 | −12.1% | 278.96 | +14.8% |
| Profit before tax | 10.52 | (13.46) | Turned profit | (2.10) | Turned profit |
| Net profit for the period | 10.52 | (13.46) | Turned profit | (2.10) | Turned profit |
| EPS, basic (₹) | 2.46 | (3.50) | not comparable | (0.93) | not comparable |
| Net margin (%) | 3.3 | -3.7 | -0.8 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 319.15 | 363.49 | −12.2% | 273.01 | +16.9% |
| Other income | 0.98 | 1.38 | −29.0% | 5.95 | −83.5% |
| Total income | 320.13 | 364.87 | −12.3% | 278.96 | +14.8% |
| Profit before tax | 10.53 | (12.32) | Turned profit | (4.88) | Turned profit |
| Net profit for the period | 10.53 | (12.32) | Turned profit | (4.88) | Turned profit |
| EPS, basic (₹) | 2.46 | (3.20) | not comparable | (1.65) | not comparable |
| Net margin (%) | 3.3 | -3.4 | -1.8 |
Consolidated
- Filed with BSE
- 25 Jul 2025, 18:05 IST
- Board meeting
- 25 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Jul 2025, 18:05 IST
- Board meeting
- 25 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE